Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 1999

View Archived Issues

Innogenetics reaches new LiPA agreement with Abbott

New antiulcer drug expected to reach Spanish market later this year

Patient accrual completed for phase III trial of Onconase

BioMarin completes financing, gears up to file first BLA

Kinetix prepares to accelerate protein kinase inhibitor drug discovery programs

Company Profile: Dynamis Therapeutics

Advanced Magnetics: Q2 1999 highlights

Licensing opportunity from LG Chemical: broad-spectrum catechol-substituted cephalosporin

PathoGenesis: Q1 1999 highlights

InSite Vision signs agreement with U. of California for glaucoma gene rights

Adenosine reduces complications in CABG

Company Profile: TheRyte

Subcutaneous anti-CD3 antibody enters psoriasis trial

BMS files for approval of new indication for paclitaxel

Unimed submits NDA for Androgel

Guilford: Annual Report 1998

Azolidinedione derivatives for improving insulin resistance

Potent and selective COX-2 inhibitors in the Glaxo Wellcome pipeline

Elastase inhibitors synthesized at Glaxo Wellcome, useful for chronic bronchitis

New carbapenems with good activity against resistant Gram-positive bacteria developed at Merck

Serine protease inhibitors designed at Glaxo Wellcome

Incyte discovers novel human tumor suppressor with application in cancer, autoimmune diseases

Anti-CCR5 MAb acts as potent HIV inhibitor

Former Novo Nordisk research unit now operating as independent company

FDA approves UroCor's prostate cancer radiation implants

Development of novel antiischemic drugs at Cypros funded by NIH

Novel benzylhydroxylamine with potent and selective anti-HIV activity undergoes further testing

New epibatidine analogues with antinociceptive activity and novel mechanism of action

Takeda initiates clinical testing with osteogenesis-promoting agent

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...